Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study describes the first reported case of a 37-year-old woman developing alopecia universalis after switching from rituximab to ocrelizumab for progressive multiple sclerosis, suggesting that ocrelizumab may trigger autoimmune reactions in immunocompromised patients.

In this case report, a woman with relapsing-remitting multiple sclerosis on long-term Ocrelizumab developed alopecia areata years after treatment initiation, suggesting a need for further study of Ocrelizumab's long-term safety profile.

In this case report, the use of ocrelizumab in the second trimester of a high-risk pregnancy with active juvenile-onset systemic lupus erythematosus resulted in a successful birth without complications, although its safety in pregnancy remains unlicensed and further evaluation is needed.

This case report presents an instance of acute pancreatitis following the use of ocrelizumab and suggests that its B lymphocyte suppression may contribute to pancreatitis by affecting cytokine release and T lymphocyte regulation.

This review discusses recent adult studies on systemic lupus erythematosus treatments and explores their implications for pediatric cases, emphasizing a critical need for more pediatric-focused research.